Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma.

ABSTRACT: OBJECTIVE:To examine survival after recurrence (SAR) among women with recurrent uterine carcinosarcoma who received a taxane/platinum doublet as the first-line salvage chemotherapy. METHODS:We retrospectively examined 148 women with recurrent uterine carcinosarcoma who received salvage chemotherapy within a cohort of 906 uterine carcinosarcomas. An independent association of salvage chemotherapy type and SAR was examined with multivariate analysis. RESULTS:There were 71 (48.0%) women who received a taxane/platinum regimen. On univariate analysis, women who received a taxane/platinum doublet had a higher 2-year SAR rate compared to women who received non-taxane/platinum regimens (55.5% versus 34.8%, P<0.001). On multivariate analysis, use of taxane/platinum regimen was independently associa

SUBMITTER: Matsuo K 

PROVIDER: S-EPMC7526037 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature